Additional file 1 of Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T

Supplementary Material 1. Figure S1 Schematic diagram of the anti-gp350 CAR structure. The CAR construct includes: IgHL (Immunoglobulin heavy chain leader signal sequence), scFv (single-chain variable fragment for specific antigen recognition), IgG4 hinge (for receptor flexibility), IgG1 Fc CH3 domain (for structure stabilization), CD28TM (CD28 transmembrane domain for membrane anchoring), CD28cyto (CD28 cytoplasmic domain for costimulatory signaling), and CD3ζ (CD3 zeta chain intracellular domain for primary T-cell activation signal). The restriction sites PmlI and BamHI are indicated.